In addition, Alexza and Endo Pharmaceuticals have agreed to mutually terminate their development agreement for AZ-003 (Staccato fentanyl), a product development candidate that has completed Phase I clinical
Theragenetics, a personalised medicine diagnostics company which develops tests to improve the treatment of patients with central nervous system (“CNS”) disorders such as schizophrenia and depression. Under the
According to the company, Zavesca is the first treatment to be approved for patients with Niemann-Pick type C disease, a very rare, invariably progressive and eventually fatal neurodegenerative
“We are very pleased to add Eric’s scientific expertise and leadership to our already strong senior management team,” said Carl Hull, Gen-Probe’s president and chief operating officer. “We
For the fourth quarter of 2008, Illumina reported revenue of $160.9 million, up 43% over the $112.6 million reported in the fourth quarter of 2007 and up 7%
The capital infusion will also serve to further the development of other innovative magnetic resonance image analysis technologies designed to increase physician productivity and accuracy, improve patient outcomes,
The funds will enable DNA Therapeutics to advance the vectorization and the additional proofs of concept, and to achieve regulatory preclinical studies of its lead product, named Dbait.
Underwriters Laboratories certified the product on January 22, 2009 opening the way to customer deliveries of FreeHand throughout Europe and those other countries whose certification or licensing requirements
Novo Nordisk has previously reached a corporate decision to exit the oncology therapeutic area, resulting in the suspension of all ongoing oncology programs. Under the terms of the
This agreement resolves the parties’ dispute that was pending in the District Court of Texas. Acacia Research’s subsidiaries develop, acquire, and license patented technologies. They control over 100
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.